KRAS and carcinoma: Despite the fact that EGFR is overexpressed in numerous carcinomas and thus represents a promising target for therapeutic intervention, mutations of the PI3-kinase or K-Ras result in a lack of response to conventional anti-EGFR therapy (38, 39).